Israel Cancer Research Fund (ICRF) – Montreal

Background

The Israel Cancer Research Fund (ICRF) is a nonprofit organization dedicated to supporting innovative cancer research conducted by Israeli scientists. Established in 1975 by a group of physicians, scientists, and philanthropists, ICRF's mission is to fund groundbreaking cancer research in Israel, aiming to eliminate suffering caused by cancer. The organization envisions a world free from cancer-related suffering and emphasizes values such as innovation, conviction, research-first approach, and dedicated funding efforts.

Key Strategic Focus

ICRF's strategic focus centers on:

Funding Early-Stage Research: Prioritizing innovative projects with high potential for impact.

Supporting Israeli Scientists: Investing in the most promising Israeli researchers to advance cancer prevention, diagnosis, and treatment.

Comprehensive Research Areas: Covering a wide range of cancers, including ovarian, endometrial, prostate, thoracic, upper gastrointestinal, orthopedic, pediatric hematology, BRCA1 and BRCA2 mutations, liver, melanoma, and immunotherapy.

Financials and Funding

Since its inception, ICRF has raised over $98 million USD, funding more than 2,885 cancer research grants. The organization operates chapters in Montreal, Toronto, Connecticut, New York, Chicago, Los Angeles, Miami, and Israel, all dedicated to finding a cure for cancer.

Pipeline Development

ICRF-funded scientists have been instrumental in the development of breakthrough FDA-approved drugs, including:

Gleevec®: The first drug to directly target cancer cells, developed based on the research of ICRF grantee Dr. Eli Canaani of the Weizmann Institute of Science. Gleevec® changed the course of chronic myeloid leukemia (CML), turning it into a manageable condition.

Doxil®: The first drug encapsulated in a liposome for direct delivery to a tumor site, developed by ICRF grantee Dr. Alberto Gabizon of Shaare Zedek Medical Center. Doxil® has a prolonged duration of circulation and dramatically decreased toxicities compared to native drugs.

Velcade®: A drug used to treat multiple myeloma, developed based on the research of ICRF Research Professorship Grant Recipients and Nobel Laureates Drs. Avram Hershko and Aaron Ciechanover of The Technion Israel Institute of Technology. Prior to this, there were no effective treatment options for multiple myeloma.

Technological Platform and Innovation

ICRF supports a range of technological platforms and innovative research methodologies, including:

Nano-Medicine: Advancing targeted drug delivery systems to improve treatment efficacy and reduce side effects.

Immunotherapy: Developing therapies that harness the body's immune system to fight cancer.

Stem Cell Research: Exploring the potential of stem cells in regenerating damaged tissues and treating various cancers.

Targeted Therapies: Creating treatments that specifically target cancer cells while sparing healthy ones.

Leadership Team

The Montreal chapter of ICRF is led by:

Jeffrey Bernstein: President

Alexandra Schwartz: CEO

Sheryl Ramroop: Office Manager

Robert Bard: International Liaison, Past President

The Board of Directors includes members such as Elaine Browman, Phyllis Brull, Leslie Cons, Brian Etcovitch, Tamar Gordon, Bruce Isenberg, Andrea Kessous, Leah Moss Bard, Heather Paperman, Joseph Paperman, Sheryl Rosen Adler, Elyse Rosen, Bonnie Rothstein, Allen Rubin, Sarah Rubin, Bernard Sepinwall, Sharyn Sepinwall, Arlene Silver, Robert Spector, Heidi Strohl, Angela Tietolman, Fred Wenger, and Karen Zajdman.

Leadership Changes

No recent significant changes or appointments within the company's leadership have been reported.

Competitor Profile

Market Insights and Dynamics

The cancer research funding landscape is highly competitive, with numerous organizations striving to support innovative research and development. The market is characterized by a growing emphasis on personalized medicine, immunotherapy, and targeted treatments.

Competitor Analysis

Key competitors include:

Cancer Research Institute (CRI): A leading nonprofit organization dedicated exclusively to transforming cancer patient care by advancing immunotherapy research. CRI has invested $344 million in support of research conducted by immunologists and tumor immunologists at the world’s leading medical centers and universities.

Samuel Waxman Cancer Research Foundation (SWCRF): Focuses on funding collaborative, cross-institutional research to eradicate cancer. SWCRF has partnered with ICRF to address the rising incidence of cancer due to aging.

Quebec Cancer Foundation: A Quebec-based nonprofit organization aiming to improve care for Quebecers suffering from cancer and enhance the quality of life for patients and their relatives.

Strategic Collaborations and Partnerships

ICRF has engaged in significant collaborations to strengthen its research initiatives:

The Immunotherapy Promise Initiative: A partnership with the Cancer Research Institute to promote research into immunotherapy, aiming to engage and enhance a patient’s own immune system to detect and eliminate cancer cells.

Aging and Cancer Research Program: A collaborative program with the Samuel Waxman Cancer Research Foundation to address the rising incidence of cancer due to aging, allocating up to $1 million over three years.

Operational Insights

ICRF's strategic considerations include:

Global Reach with Local Impact: While focusing on Israeli scientists, ICRF's research funding has a significant impact in Montreal, across Canada, and throughout the world.

Rigorous Grantmaking Process: Overseen by a volunteer Scientific Review Panel comprising leading physicians and scientists from major research institutions throughout North America, ensuring that only the most promising research projects receive funding.

Strategic Opportunities and Future Directions

ICRF's strategic roadmap includes:

Expanding Research Funding: Continuing to raise funds to support innovative cancer research projects in Israel and locally in Montreal.

Enhancing Collaborative Efforts: Strengthening partnerships with other research organizations to leverage resources and expertise.

Fostering Innovation: Supporting cutting-edge research in areas such as immunotherapy, nano-medicine, and targeted therapies to accelerate the development of effective cancer treatments.